These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7128166)

  • 1. Clinical problems of renal osteopathy in patients on hemofiltration.
    Schulz W; Baier E; Hümpfner A; Delling G
    Contrib Nephrol; 1982; 32():86-91. PubMed ID: 7128166
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
    Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
    Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
    [No Abstract]   [Full Text] [Related]  

  • 4. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency.
    Duursma SA; Visser WJ; Mees EJ; Njio L
    Calcif Tissue Res; 1974; 16(2):129-38. PubMed ID: 4447892
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum hydroxyproline and renal osteodystrophy in patients maintained on haemodialysis.
    Goulding A; McChesney R; Irvine RO; Dixon SR
    N Z Med J; 1974 Dec; 80(530):540-4. PubMed ID: 4615274
    [No Abstract]   [Full Text] [Related]  

  • 8. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 9. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 10. Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis.
    Gokal R; Ramos JM; Ellis HA; Parkinson I; Sweetman V; Dewar J; Ward MK; Kerr DN
    Kidney Int; 1983 Jan; 23(1):15-21. PubMed ID: 6834691
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 12. [Surgical treatment of secondary hyperparathyroidism].
    D'Alonzo U
    Minerva Med; 1985 Mar; 76(9-10):389-91. PubMed ID: 3982695
    [No Abstract]   [Full Text] [Related]  

  • 13. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)].
    Pogglitsch H; Schmidberger H; Gell G
    MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy].
    Di Landro D; Zanatta GP; Simioni N; Pinzani A; Zotti D; Perin N; Bertoli M; Naso A; Ruffatti A; Gasparotto ML
    Minerva Med; 1985 Mar; 76(9-10):419-23. PubMed ID: 3982699
    [No Abstract]   [Full Text] [Related]  

  • 16. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 17. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations.
    Meany DL; Jan de Beur SM; Bill MJ; Sokoll LJ
    Clin Chem; 2009 Sep; 55(9):1737-9. PubMed ID: 19717659
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of CKD-MBD phenotype on health-related quality of life in patients receiving maintenance hemodialysis: A cross-sectional study.
    Luo L; Chen Q
    J Int Med Res; 2020 Feb; 48(2):300060519895844. PubMed ID: 32054360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone, calcium and phosphate balance in hemofiltration.
    Fuchs C; Doht B; Dorn D; McIntosh C; Ritter D; Scheler F
    J Dial; 1977; 1(6):631-40. PubMed ID: 608872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.